Bayer's Q2 Result: 60%-Plus Rally Meets a €33.6 Billion Debt Test

The rally has improved sentiment, but cash conversion is still the real test

Bayer's rebound looks more like a trust trade than a fully earned recovery. The stock is still up more than 60% over the past year, which suggests investors are responding to signs that some of the company's biggest uncertainties may be easing. What is still missing is a clearer picture of how quickly operations and litigation containment can turn into usable cash and meaningful debt reduction.

There are legitimate reasons for that cautious optimism. Bayer says it has made decisive progress on its long-term strategic priorities, including a landmark Supreme Court ruling that strengthens its position in glyphosate litigation and improves the backdrop for the proposed class settlement. Management also maintained its full-year outlook and said net financial debt is now expected to be lower than previously projected. Those are meaningful steps, but they do not yet answer the bigger question of how fast the business can free up cash.

The balance-sheet pressure is still very visible. Bayer still has net financial debt of €33.647 billion, while free cash flow fell to minus €371 million, partly because of settlement payments. The operating engine is improving, especially in Crop Science, but the company still needs litigation costs to stabilize and cash flow to recover before the recovery trade feels fully secure.

Crop Science is the strongest argument for Bayer's turnaround case

If Bayer still has a case, it is because the strongest part of the business is holding up well. In the second quarter, the group produced currency- and portfolio-adjusted sales of €10.872 billion and EBITDA before special items of €2.144 billion. Those results help keep the whole company in play, but the more important signal is coming from Crop Science.

Why Crop Science matters most right now

Crop Science is doing the heavy lifting. Bayer said the division delivered 5.5% sales growth in the first half and reached a 31% EBITDA margin. That mix of growth and profitability looks more like a working core business than a pure recovery narrative, with gains supported by seeds and traits as well as additional licensing revenue.

That matters because the rest of the group is not posting a flawless scorecard. Pharmaceuticals sales were flat, and Consumer Health showed only modest sales growth while earnings softened. The bullish argument, therefore, is not that every segment is firing on all cylinders. It is that a strong, higher-margin Crop Science business can do more than carry the group and gradually change how investors value the company.

Why the earnings picture is still mixed

The positive operating trends have not yet translated into a clean earnings rebound. Bayer reported core earnings per share of €0.95, which was 16.7% below the prior-year period. Management attributed part of that decline to non-recurring tax and reconciliation benefits in 2025, so this quarter may look weaker only by comparison. Still, until stronger segment performance shows up more clearly in earnings and cash flow, the story remains more about renewed confidence than a full earnings reassessment.

Debt, cash flow, and litigation approval still drive the stock

The next move in Bayer shares will depend less on another optimistic operating update and more on whether improved operations can start to support a very heavy balance sheet.

What the market is really pricing

For now, sentiment matters, but the scoreboard is still balance-sheet math. Bayer still has net financial debt of €33.647 billion, and the latest quarter produced free cash flow of minus €371 million, partly due to settlement payments. The company is also working through a proposed class settlement, with litigation provisions raised to €11.8 billion and management warning that settlement payments could drive negative free cash flow this year.

That is why management's updated guidance helps, but does not settle the debate. Confirming the currency-adjusted Group outlook and saying net financial debt is expected to be lower than originally projected are positive steps. But they do not yet show how quickly Bayer can move from containment to tangible debt reduction.

The near-term catalyst investors cannot ignore

The most visible near-term test is legal, not operational. Bayer said August 19, 2026 is the date for the final approval hearing in Missouri. If that hearing improves the odds around the proposed $7.25bn class-action settlement framework, the market may become more confident that the cash drain has a ceiling. If it does not, some of the recent progress could unwind quickly.

Treat Bayer as a proof story for now. The better businesses inside the company help, but another rerating likely requires clearer evidence that cash generation can start paying down the baggage.